Tharimmune Corp (THAR) - Market Capitalization

The Tharimmune, Inc. (THAR) ecosystem develops advanced therapies for liver and skin lesions by implementing specific antibodies to alleviate chronic pruritus. The business currently relies on intensive R&D and clinical trials of new immunomodulators. Its technology stack is augmented by AI and robotics to accelerate the selection of anti-tumor compounds. Market capitalization stands at 0.19, as confirmed by the price evolution charts provided below.

THAR tharimmune.com: Market Value in the range 02/21/2024 - 02/18/2026

Metric breakdowns and analytics for Tharimmune Corporation (THAR)

- current price and projected stock value:

Stock Price Tharimmune|THAR - Fair Value Consensus

- market capitalization indicators:

Market Capitalization Tharimmune Corporation|THAR - Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Tharimmune|THAR - Accounting Value of Company|Market Capitalization to Book Value Ratio tharimmune.com|THAR - Cumulative Company Assets

- issuer credit burden and liquidity indicators:

- business earnings and investment ratios data:

THAR - Final Profit|Future Profit Tharimmune, Inc.|THAR - Company Value to Net Income|Forward P/E Multiple Tharimmune Corp|THAR - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio Tharimmune Corporation|THAR - Operating profit EBITDA|Earnings per share for the last twelve months Tharimmune|THAR - Earnings per share for the trailing year|Quarterly EPS earnings growth tharimmune.com|THAR - Earnings per share growth rate in current year|Expected earnings per share growth for next year Tharimmune, Inc.

Fundamental company valuation:Tharimmune THAR

The development progress of drugs by Tharimmune, Inc. (THAR) to combat autoimmune inflammation is directly reflected in the company's market capitalization. This indicator represents the aggregate market value of all the issuer's outstanding shares. The calculation is performed by multiplying the current quote by the total number of securities in circulation. For a biotech startup sustained by grants, this metric serves as a gauge of market confidence in future research. Growth in this metric confirms the capitalization of the business's intellectual potential.

Competitors of Tharimmune, Inc. (THAR)